Biokin's EGFRxHER3 ADC succeeds in Chinese lung cancer trial, boosting BMS global hopes
Chinese biotech Biokin reported that its bispecific antibody-drug conjugate targeting EGFR and HER3 met its primary endpoint in a late-stage trial for a genetically defined lung cancer subtype in China. The positive result raises confidence in a parallel global study being run by partner Bristol Myers Squibb. This marks the fourth successful cancer trial for the candidate in China.
Related stories
Zipalertinib succeeds in Phase 3 trial for EGFR-mutant lung cancer, challenging Rybrevant · Cancer research
Definium Therapeutics' oral LSD candidate succeeds in initial Phase 3 trial for generalized anxiety disorder · Mental health
AstraZeneca halts late-stage lung cancer trial; U.S. drug prices decline · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China.” Browse more stories.